ClinicalTrials.gg
WithdrawnNCT03566290Updated Mar 1, 2024

Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

A Phase 2 interventional study of GTx-024 in Stress Urinary Incontinence, sponsored by GTx. Withdrawn at 46 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by GTx · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Development of investigational product was halted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.

Enrollment
157th of 163
0 · median 98
Started
2018
with 9 others
Phase 2
12 of 189
1 open now
Registered
105th of 189
by date
Lead sponsor
4 of 189
GTx

Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 157th largest by enrollment of the 163 interventional ones that give a count, is one of 10 that started in 2018, is one of 12 in phase 2, and was the 105th registered.

Urinary Incontinence, Stress

653 studies on the registry are indexed under Urinary Incontinence, Stress; 122 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Incontinence, Stress studies recruiting now, 42 (56%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

This open-label extension study, for subjects from the G201002 study, will provide additional long-term safety and tolerability data for GTx-024. All subjects in this study will receive GTx-024 3 mg orally, once daily.

03

Conditions studied

  • Stress Urinary Incontinence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be an eligible subject from G201002, where an eligible subject is defined as:

    1. one of the first 225 subjects who were randomly assigned to the placebo group in G201002 and who have completed the required treatment and durability periods of that study, or;
    2. any subject from 226 onwards, who was randomly assigned to any treatment group and who completed the required treatment and follow-up periods of that study
  • Be able to read, understand, and provide written, dated, prior to enrollment in the current study and be likely to comply with the study protocol and communicate with study personnel about AEs and other information
  • Provide written consent to participate in the study within the following timeframes:

    1. for G201002 Subjects 1-225, within 30 days after unblinding of G201002 (subjects who consent to participate in G201003 will be allowed to discontinue from that study and consent to this study upon unblinding of G201002)
    2. for G201002 Subjects 226-493, within 30 days of completing both the treatment and follow-up periods of G201002
  • Agree to maintain a stable dose of any medication known to affect lower urinary tract function, including but not limited to anticholinergics, tricyclic antidepressants, beta-3 adrenergic agonists, or α-adrenergic blockers, throughout the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Starts any new treatment (medication, pelvic floor physical therapy, or other treatment known to impact the pelvic floor) after completing G201002 that is known or suspected to affect lower urinary tract function, including vaginal rejuvenation
  • Subject is currently taking systemic sex-hormone products (excludes intravaginal application of estradiol topical/tablet agents and hormones delivered via vaginal rings)
  • Has a current cancer diagnosis (with the exception of nonmelanoma skin cancer) or any history of breast or endometrial cancer
  • Has a known history or current episode of:

    1. Stage ≥ 2 hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) at screening and/or baseline. Subjects with hypertension that has been treated and controlled with medication for ≥ 2 weeks prior to screening are eligible for participation
    2. Recent myocardial infarction or arterial or venous thromboembolic event (within 1 year) or a history of more than 1 myocardial infarction or arterial or venous thromboembolic event
    3. Cardiac-related syncopal event within the past year
    4. Cardio or cerebral vascular disease requiring surgical intervention (e.g., bypass surgery, angioplasty). For subjects with previous stent placement, please contact the medical monitor
    5. Congestive heart failure of Stage > 2 according to New York Heart Association criteria
    6. Angina pectoris
  • Has a current or past history of any physical condition that, in the investigator's opinion, might put the subject at risk, impact the absorption of the study drug, or interfere with interpretation of study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Open-Label Extension, 3 mg GTx-024

    Eligible subjects from G201002

    Drug: GTx-024

Interventions

  • Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.

    Also known as: enobosarm

06

What researchers measure

Primary outcomes

  1. Safety of GTx-024, adverse events

    Change from baseline in incidence of adverse events

    Time frame: baseline through study completion, an average of 1 year

  2. Safety of GTx-024, liver function test

    Change from baseline in liver function test

    Time frame: baseline through study completion, an average of 1 year

  3. Safety of GTx-024, lipid panel

    Change from baseline in lipid panel

    Time frame: baseline through study completion, an average of 1 year

  4. Safety of GTx-024, sex-hormone binding globulin levels

    Change from baseline in sex-hormone binding globulin levels

    Time frame: baseline through study completion, an average of 1 year

  5. Safety of GTx-024, testosterone levels

    Change from baseline in testosterone levels

    Time frame: baseline through study completion, an average of 1 year

  6. Safety of GTx-024, endometrial stripe thickness

    Change from baseline in endometrial stripe thickness as measured by transvaginal ultrasound

    Time frame: baseline through study completion, an average of 1 year

  7. Safety of GTx-024, weight

    Change from baseline weight

    Time frame: baseline through study completion, an average of 1 year

Secondary outcomes

  1. Efficacy of GTx-024, stress incontinence

    Change from baseline in the mean number of stress incontinence episodes per day

    Time frame: baseline through study completion, an average of 1 year

  2. Efficacy of GTx-024, patient global impression of severity

    Change in patient global impression of severity (PGI-S; scale: 1-normal, 2-mild, 3-moderate, 4-severe; representing severity of urinary tract dysfunction)

    Time frame: baseline through study completion, an average of 1 year

  3. Efficacy of GTx-024, patient global impression of improvement

    Change in patient global impression of improvement (PGI-I; scale: 1-very much better, 2-much better, 3-a little better, 4-no change, 5-a little worse, 6-much worse, 7-very much worse; representing change in urinary tract dysfunction from initiation of therapy)

    Time frame: baseline through study completion, an average of 1 year

  4. Efficacy of GTx-024, urge incontinence

    Change from baseline in the mean number of urge incontinence episodes per day

    Time frame: baseline through study completion, an average of 1 year

  5. Efficacy of GTx-024, total incontinence

    Change from baseline in the mean number of total (stress + urge) incontinence episodes per day

    Time frame: baseline through study completion, an average of 1 year

07

Study locations

46 sites
  • Urology Center of Alabama
    Homewood, Alabama 35209, United States
  • Coastal Clinical Research Inc
    Mobile, Alabama 36608, United States
  • Alaska Clinical Research Center
    Anchorage, Alaska 99503, United States
  • Genitourinary Surgical Consultants
    Denver, Colorado 80220, United States
  • Urology Associates Research
    Englewood, Colorado 80113, United States
  • Women's Health Specialty Care
    Farmington, Connecticut 06032, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • So. Florida Medical Research
    Aventura, Florida 33180, United States
  • Tampa Bay Medical Research Inc
    Clearwater, Florida 33761, United States
  • Midland Florida Clinical Research Center LLC
    DeLand, Florida 32720, United States
  • Medical Research of Florida
    Miami, Florida 33186, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060, United States
  • Mount Vernon Clinical Research LLC
    Sandy Springs, Georgia 30328, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83221, United States
  • Idaho Urologic Institue
    Meridian, Idaho 83642, United States
  • First Urology PSC
    Jeffersonville, Indiana 47130, United States
  • Iowa Clinic
    West Des Moines, Iowa 50266, United States
  • DelRicht Clinical Research, LLC
    New Orleans, Louisiana 70115, United States
  • Regional Urology
    Shreveport, Louisiana 71106, United States
  • Chesapeake Urology Associates PA
    Hanover, Maryland 21076, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Bay State clinical Trials
    Watertown, Massachusetts 02472, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • William Beaumont Hospital Urology Research
    Royal Oak, Michigan 48073, United States
  • Women's Clinic of Lincoln
    Lincoln, Nebraska 68510, United States
  • Sheldon J Freedman MD Ltd
    Las Vegas, Nevada 89144, United States
  • Premier Urology Group, LL
    Edison, New Jersey 08837, United States
  • Lawrence Obs Gyn clinical Research
    Lawrenceville, New Jersey 08648, United States
  • Accumed Research Associates
    Garden City, New York 11530, United States
  • Manhattan Medical Research Practice PLLC
    New York, New York 10016, United States
  • Premier Medical Group
    Poughkeepsie, New York 12601, United States
  • Circuit Clinical
    West Seneca, New York 14224, United States
  • American Health Research Inc
    Charlotte, North Carolina 28207, United States
  • Eastern Carolina Women's
    New Bern, North Carolina 28562, United States
  • The Urology Group
    Cincinnati, Ohio 45212, United States
  • Aventiv Research
    Columbus, Ohio 43213, United States
  • Urologic Consultants of Southeastern PA LLP
    Bala-Cynwyd, Pennsylvania 19004, United States
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Elligo - Austin Area OBGYN
    Austin, Texas 78758, United States
  • Urology Clinics of North Texas
    Dallas, Texas 75231, United States
  • Urology San Antonio Research PA
    San Antonio, Texas 78229, United States
  • Synexus Clinical Research Advantage, Inc. - Wasatch Peak Family Practice
    Layton, Utah 84041, United States
  • Urology of Virginia
    Virginia Beach, Virginia 23462, United States
  • Seattle Womens: Health, Research, Gynocology
    Seattle, Washington 98105, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Sep 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2018
First posted
Jun 25, 2018
StartActual
Jun 28, 2018
Primary completionActual
Sep 21, 2018
CompletionActual
Sep 21, 2018
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03566290
Lead sponsor
GTx
Responsible party
Sponsor
First posted
Jun 25, 2018
Start date
Jun 28, 2018
Primary completion
Sep 21, 2018
Completion
Sep 21, 2018
Last update
Mar 1, 2024

Study contacts

Kenneth Peters, MD
principal investigator · Professor & Chair, Department of Urology, Oakland University Wm. Beaumont School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion